Clinical Characteristics of Pramipexole-Induced Peripheral Edema

Abstract

Peripheral edema should be included among the potential adverse events associated with pramipexole therapy.

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease

“…35,36 The development or worsening of edema was associated with initial pramipexole treatment, comorbid cardiac disease, and female gender. Edema is a recently recognized complication of therapy in PD, 10 and pramipexole treatment in particular, 11 though the frequency of this complication has rarely been reported. A safety dose ranging study of pramipexole in subjects with early PD did not report edema as a complication over a 10-week observation period.…”

“…Somnolence is increasingly recognized as a significant problem in PD, 7 being associated with worse quality of life and sudden onset of sleep while driving 8,9 ; however, the rate of this complication upon initiation of dopaminergic therapy is unknown. Edema, which has rarely been reported in the literature 10 and in only 8% of patients initiating dopaminergic therapy with pramipexole, 11 has not been systematically evaluated in PD, but has been associated with quality of life impairment in other populations. 12 Hallucinations are a well documented complication of dopaminergic therapy and represent a significant source of morbidity in PD, as well as being associated with an increased risk of nursing home placement and mortality 13,14 ; however, hallucinations are generally believed to be a complication of more advanced disease.…”

Current approaches to the treatment of Parkinson’s disease

“…In contrast to the traditional DA agonists (bromocriptine and pergolide), pramipexole and ropinirole are nonergolines and therefore are expected to have a lower risk of complications such as peptic ulcer disease, vasoconstrictive effects, erythromelalgia, pulmonary and retroperitoneal fibrosis, and valvular heart disease (Tintner et al 2005; Roth 2007; Zanettini et al 2007). Pramipexole often causes dose-dependent and idiosyncratic peripheral edema (Tan and Ondo 2000). Because of the potential for valvular heart disease, the ergot dopamine agonists have been essentially discontinued from medical practice.…”

Comorbid states in Parkinson’s disease: an effect of MAO-B inhibitors

“…АДР являются мощ-ными психотогенными препаратами, что проявляется в развитии преимущественно зрительных галлюцинаций, особенно у пожилых пациентов и у пациентов с когнитив-ными нарушениями [8], они могут вызывать повышенную дневную сонливость и приступы засыпания в дневные часы [9], нарушения импульсного контроля [10,11]. Все АДР могут провоцировать выраженный отек голеней, ко-торый возникает через несколько лет терапии [12,13]. Ча-сто все эти симптомы требуют прекращения приема АДР, что может приводить к такому осложнению, как развитие синдрома отмены.…”